Key facts
- It has raised $15.7M; the latest was Accelerator/Incubator ($100K) in Jan 2025.
- Notable investors include Creative Destruction Lab, Google for Startups, 8VC, Global Founders Capital, University of Toronto — 29 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 29 names
- ·Watchlist + deal alerts for ProteinQure
- ·The full record, as it builds
Funding rounds
No funding rounds for ProteinQure are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ProteinQure
Operator of a biotech company intended to focus on the design of novel exotic peptides with broad therapeutic applications. The company specializes in leveraging quantum computing, molecular simulations, and reinforcement learning to facilitate novel therapeutics engineering, enabling researchers and drug developers to engineer and design protein structures with efficiency.
- Sector
- Healthcare
- HQ
- Toronto, Canada
- Founded
- 2017
- Employees
- 34
- Website
- proteinqure.com/
- Ownership
- Privately Held (backing)
ProteinQure doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ProteinQure shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ProteinQure in its N-PORT filings yet. We sweep new filings monthly.